Search - tctmd.com

Displaying 141 - 160 of 261

Sort: Relevancy | Date

Presentation TCT 2017

TCT 571: Different Tissue Morphology of In-stent Restenosis in Hemodialysis Patient Compared With Non-hemodialysis Patients: A Prospective Multicenter Optical Coherence Tomography Registry

Presenter: Francesco Prati, Renu Virmani, Yoshinori Nagasawa, MD

October 31, 2017

Presentation TCT 2017

Management of External Iliac Artery In-stent Restenosis

Presenter: Ehrin J. Armstrong, Brian G. DeRubertis

October 31, 2017

Presentation TCT 2017

DCB Preclinical Perspectives: Mechanisms and Experimental Safety and Efficacy of Older, Current, and Futuristic DCB

Presenter: Robert A. Byrne, Ran Kornowski, Juan F. Granada

October 30, 2017

$Treatment of Refractory In-Stent Restenosis State-of-the-Art Review: From Standard Approaches to Parental Drugs and Vascular Brachytherapy$

Presentation TCT 2017

Treatment of Refractory In-Stent Restenosis State-of-the-Art Review: From Standard Approaches to Parental Drugs and Vascular Brachytherapy

Presenter: Robert A. Byrne, Ran Kornowski, Ron Waksman

October 30, 2017

News Conference News TCT 2017

DARE Supports Drug-Coated Balloon as Alternative to DES for Any In-Stent Restenosis

Todd Neale

October 30, 2017

Presentation TCT 2017

Treatment of First-time In-Stent Restenosis State-of-the-Art Review: From Lesion Preparation and Imaging to Restenting to DCB

Presenter: Robert A. Byrne, Ran Kornowski, Fernando Alfonso

October 30, 2017

Presentation TCT 2017

Does DCB Technology Have an Important Role in Treatment of De Novo Coronary Artery Disease? If Not Today, Tomorrow?

Presenter: Robert A. Byrne, Ran Kornowski, Bernardo Cortese

October 30, 2017

Presentation TCT 2017

Drug-Coated Coronary Balloon Therapy: Current State-of-the-Art

Presenter: Robert A. Byrne, Ran Kornowski, Bruno Scheller

October 30, 2017

Presentation TCT 2017

DARE: A Randomized Trial of a Drug-Eluting Balloon vs a Metallic DES in Patients With Coronary Artery In-Stent Restenosis

Presenter: Fernando Alfonso, Jose P.S. Henriques

October 30, 2017

News Conference News TCT 2016

Novel SES Fails to Match Xience EES for Chronic Total Occlusions

Yael L. Maxwell

November 08, 2016

News Conference News TCT 2016

RIBS VI: Absorb BVS Safe in In-Stent Restenosis but Fails to Best Xience Metallic Stent

Michael O'Riordan

November 08, 2016

News Conference News TCT 2016

No Scares From SCAAR: Stent Thrombosis Rates in Newest DES Are Similar—and Low

Shelley Wood

November 07, 2016

News Industry News TCT 2016

Hybrid Sirolimus-Eluting Stents with Biodegradable Polymer Did Not Improve Angiographic Outcomes Compared to Everolimus-Eluting Stents with Durable Polymer in Treatment of Chronic Total Occlusions

November 02, 2016

Presentation TCT 2016

RIBS VI: A Prospective, Multicenter Registry of Bioresorbable Vascular Scaffolds in Patients With Coronary Artery Bare Metal or Drug-Eluting In-Stent Restenosis Six Month-Nine Month Clinical and Angiographic Follow-up Results

Presenter: Gary S. Mintz, Robert-Jan van Geuns, Fernando Alfonso

November 02, 2016

Presentation TCT 2016

DEBATE: DCB for In-Stent Restenosis: Does the Current Data Support Broad Adoption? Yes! The Data is Solid and DCB Should be the Treatment of Choice!

Presenter: Fernando Alfonso, Juan F. Granada, Bruno Scheller

November 01, 2016

Presentation TCT 2016

Sirolimus Angioplasty Balloon for In-Stent Restenosis (SABRE) Trial: 6-Month Angiographic and 1-Year Clinical Follow Up

Presenter: Fernando Alfonso, Ran Kornowski, Pieter R. Stella

November 01, 2016

Presentation TCT 2016

Nanoparticle Sirolimus Coated Balloon for the Treatment of In-Stent Restenosis: Results from the Nanolute Registry

Presenter: Fernando Alfonso, Ran Kornowski, Bernardo Cortese

November 01, 2016

News Conference News TCT 2016

New BRS Studies Show Promise for Second-Generation Devices With Thinner Struts

Yael L. Maxwell

October 31, 2016

News Conference News TCT 2016

‘Encouraging’ Preliminary Results Seen With Novel, Polymer-Free, Drug-Filled Stent

Todd Neale

October 31, 2016

Presentation TCT 2016

Case Presentation: Evaluation and Management of Recurrent DES Restenosis

Presenter: Fernando Alfonso, Stephan Windecker, Adnan K. Chhatriwalla

October 30, 2016

Advertisement

TCT 571: Different Tissue Morphology of In-stent Restenosis in Hemodialysis Patient Compared With Non-hemodialysis Patients: A Prospective Multicenter Optical Coherence Tomography Registry

Management of External Iliac Artery In-stent Restenosis

DCB Preclinical Perspectives: Mechanisms and Experimental Safety and Efficacy of Older, Current, and Futuristic DCB

Treatment of Refractory In-Stent Restenosis State-of-the-Art Review: From Standard Approaches to Parental Drugs and Vascular Brachytherapy

DARE Supports Drug-Coated Balloon as Alternative to DES for Any In-Stent Restenosis

Treatment of First-time In-Stent Restenosis State-of-the-Art Review: From Lesion Preparation and Imaging to Restenting to DCB

Does DCB Technology Have an Important Role in Treatment of De Novo Coronary Artery Disease? If Not Today, Tomorrow?

Drug-Coated Coronary Balloon Therapy: Current State-of-the-Art

DARE: A Randomized Trial of a Drug-Eluting Balloon vs a Metallic DES in Patients With Coronary Artery In-Stent Restenosis

Novel SES Fails to Match Xience EES for Chronic Total Occlusions

RIBS VI: Absorb BVS Safe in In-Stent Restenosis but Fails to Best Xience Metallic Stent

No Scares From SCAAR: Stent Thrombosis Rates in Newest DES Are Similar—and Low

Hybrid Sirolimus-Eluting Stents with Biodegradable Polymer Did Not Improve Angiographic Outcomes Compared to Everolimus-Eluting Stents with Durable Polymer in Treatment of Chronic Total Occlusions

RIBS VI: A Prospective, Multicenter Registry of Bioresorbable Vascular Scaffolds in Patients With Coronary Artery Bare Metal or Drug-Eluting In-Stent Restenosis Six Month-Nine Month Clinical and Angiographic Follow-up Results

DEBATE: DCB for In-Stent Restenosis: Does the Current Data Support Broad Adoption? Yes! The Data is Solid and DCB Should be the Treatment of Choice!

Sirolimus Angioplasty Balloon for In-Stent Restenosis (SABRE) Trial: 6-Month Angiographic and 1-Year Clinical Follow Up

Nanoparticle Sirolimus Coated Balloon for the Treatment of In-Stent Restenosis: Results from the Nanolute Registry

New BRS Studies Show Promise for Second-Generation Devices With Thinner Struts

‘Encouraging’ Preliminary Results Seen With Novel, Polymer-Free, Drug-Filled Stent

Case Presentation: Evaluation and Management of Recurrent DES Restenosis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content